Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,397 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 2 Interventional Results available

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

NCT00113217
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 27, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

NCT04161755
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Atezolizumab, RO7198457, mFOLFIRINOX
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

NCT02230306
View directory record Official record
Conditions
Active Melanoma Brain Metastases
Interventions
Cobimetinib, Vemurafenib
Drug
Lead sponsor
Melissa Burgess, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
New Haven, Connecticut • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

NCT00968435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
bevacizumab, cisplatin, cetuximab, radiation therapy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

NCT00417976
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Bevacizumab, Infusional 5-Fluorouracil
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 27, 2026, 5:49 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

NCT00227617
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions
bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
2
States / cities
San Francisco, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

NCT04327791
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir, Placebos
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Cooperstown, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

NCT06555133
View directory record Official record
Conditions
Colorectal Carcinoma Metastatic in the Liver
Interventions
yttrium-90 radioembolization
Combination Product
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935
View directory record Official record
Conditions
Ocular Cicatricial Pemphigoid
Interventions
Rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Faricimab
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

NCT05673876
View directory record Official record
Conditions
Acute Graft-versus-host Disease
Interventions
GDC-8264
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01633970
View directory record Official record
Conditions
Cancer
Interventions
5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Early Phase 1 Interventional

Rituximab in the Treatment of Idiopathic Membranous Nephropathy

NCT00405340
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 27, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT03650413
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

NCT00607113
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Avastin, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962
View directory record Official record
Conditions
Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions
Autogene cevumeran, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

NCT04919382
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Temozolomide
Biological · Drug
Lead sponsor
Dwight Owen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Study of Pulmozyme to Treat Severe Asthma Episodes

NCT00169962
View directory record Official record
Conditions
Asthma
Interventions
rhDNAse (pulmozyme)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470
View directory record Official record
Conditions
Acute Graft-versus-host Disease
Interventions
Efmarodocokin Alfa
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02219724
View directory record Official record
Conditions
Neoplasms
Interventions
MOXR0916
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 27, 2026, 5:49 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT05961696
View directory record Official record
Conditions
Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
Mosunetuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

NCT01201915
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 27, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, DLBCL, Diffused Large B Cell Lymphoma, DLBCL NOS
Interventions
P-CD19CD20-ALLO1, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2041
U.S. locations
16
States / cities
Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 27, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT01149850
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions
bevacizumab, temozolomide, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis, DNA methylation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 5:49 PM EDT